Alnylam Pharmaceuticals, Inc.
ALNY · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.13 | -10.03 | 4.71 | 3.57 |
| FCF Yield | 0.52% | 0.33% | -0.36% | -0.34% |
| EV / EBITDA | 206.02 | 2,331.78 | 3,205.39 | -227.35 |
| Quality | ||||
| ROIC | 11.19% | -0.89% | 0.76% | -1.42% |
| Gross Margin | 84.21% | 81.52% | 88.04% | 82.67% |
| Cash Conversion Ratio | 1.29 | -2.32 | 2.06 | 1.13 |
| Growth | ||||
| Revenue 3-Year CAGR | 23.03% | 25.77% | 27.11% | 29.41% |
| Free Cash Flow Growth | 124.45% | 209.55% | -22.68% | -362.57% |
| Safety | ||||
| Net Debt / EBITDA | 4.32 | 86.34 | 148.63 | -12.61 |
| Interest Coverage | 8.29 | -0.40 | 0.47 | -2.70 |
| Efficiency | ||||
| Inventory Turnover | 2.62 | 1.99 | 1.08 | 1.31 |
| Cash Conversion Cycle | 50.26 | 46.64 | 23.01 | 52.83 |